Nanomedicine is a reality of medical research and clinical practice, and it offers new and promising approaches to fundamental problems in medicine. Most prominent are the early detection of neoplastic disease and the individualized treatment of metastases. These potentially transformational developments require careful scrutiny of the potential impact of nanomedicine on society, so that the community can guide its deployment in keeping with the fundamental tenets of medical ethics.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/clpt.2008.276 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
bark extract reduces the impact of infection on C57BL/6 but not on BALB/c mice ().
Parasitology
January 2025
Department of Animal and Veterinary Sciences, Scotland's Rural College (SRUC), Edinburgh, UK.
Plant secondary metabolites (PSMs) may improve gastrointestinal health by exerting immunomodulatory, anti-inflammatory and/or antiparasitic effects. Bark extracts from coniferous tree species have previously been shown to reduce the burden of a range of parasite species in the gastrointestinal tract, with condensed tannins as the potential active compounds. In the present study, the impact of an acetone extract of pine bark () on the resistance, performance and tolerance of genetically diverse mice () was assessed.
View Article and Find Full Text PDFLiposomal Formulation of Hydroxychloroquine Can Inhibit Autophagy In Vivo.
Pharmaceutics
December 2024
Department of Experimental Therapeutics, BC Cancer, Vancouver, BC V5Z 1L3, Canada.
Preclinical studies have shown that the anti-malarial drug hydroxychloroquine (HCQ) improves the anti-cancer effects of various therapeutic agents by impairing autophagy. These findings are difficult to translate in vivo as reaching an effective HCQ concentration at the tumor site for extended times is challenging. Previously, we found that free HCQ in combination with gefitinib (Iressa, ZD1839) significantly reduced tumor volume in immunocompromised mice bearing gefitinib-resistant JIMT-1 breast cancer xenografts.
View Article and Find Full Text PDFPeptide-Drug Conjugate for Therapeutic Reprogramming of Tumor-Associated Macrophages in Breast Cancer.
Adv Sci (Weinh)
January 2025
Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14B, Tartu, 50411, Estonia.
In triple-negative breast cancer (TNBC), pro-tumoral macrophages promote metastasis and suppress the immune response. To target these cells, a previously identified CD206 (mannose receptor)-binding peptide, mUNO was engineered to enhance its affinity and proteolytic stability. The new rationally designed peptide, MACTIDE, includes a trypsin inhibitor loop, from the Sunflower Trypsin Inhibitor-I.
View Article and Find Full Text PDFStimuli-Responsive Nano Drug Delivery Systems for the Treatment of Neurological Diseases.
Small
January 2025
Molecular Imaging Center, National Center for Drug Screening, Stake Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, P. R. China.
Nanomaterials with unparalleled physical and chemical attributes have become a cornerstone in the field of nanomedicine delivery. These materials can be engineered into various functionalized nanocarriers, which have become the focus of research. Stimulus-responsive nanodrug delivery systems (SRDDS) stand out as a sophisticated class of nanocarriers that can release drugs in response to environmental cues.
View Article and Find Full Text PDFDISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trial.
Mult Scler
January 2025
NYU MS Comprehensive Care Center, Department of Neurology, New York University Grossman School of Medicine, New York, NY, USA.
Background: In the DISCOMS (DISCOntinuation of disease-modifying therapies (DMTs) in multiple sclerosis (MS)) randomized clinical trial, we could not demonstrate that discontinuing MS DMTs in older, stable adults was not inferior to continuing DMTs. Relapses were rare in both groups, and most new disease activity was one to two new brain magnetic resonance imaging (MRI) lesions unassociated with clinical changes.
Objective/aims: Describe results of the DISCOMS extension study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!